Zogenix Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$264.3M
Industry:Pharma
Founded:2006
Lead Investor(s):Leerink Partners LLC, Stifel

Estimated Revenue & Financials

  • Zogenix's estimated annual revenue is currently $24.1M per year.
  • Zogenix received $288.9M in venture funding in October 2017.
  • Zogenix's estimated revenue per employee is $137,829
  • Zogenix's total funding is $264.3M.

Employee Data

  • Zogenix has 175 Employees.
  • Zogenix grew their employee count by 19% last year.
  • Zogenix currently has 30 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$15.3M763%N/A-N/A
#2
N/A125N/AN/A-N/A
#3
$13.1M6523%N/A-N/A
#4
$53.1M264N/AN/A-N/A
#5
$10.1M504%N/A-N/A
#6
$13.5M6720%N/A-N/A
#7
$62.1M30910%N/A-N/A
#8
$22.5M1125%N/A-N/A
#9
N/A17N/AN/A-N/A
#10
$69.5M3462%N/A-N/A
Missing a competitor? Contribute!?
Submit

Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning. We seek best-in-class leaders with scientific, medical and commercial expertise in the therapeutic areas in which we participate. By sharing a collective passion for making a difference in the lives of patients we serve, our unique company culture thrives through the principles of ethical decision making, open communication and collaboration.

keywords:Biotechnology,Healthcare,Pharmaceuticals

175

Number of Employees

$24.1M

Revenue (est)

30

Current Jobs

19%

Employee Growth %

$264.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Zogenix News

12-Sep-19 - Zogenix Completes Acquisition of Modis Therapeutics, Inc.

EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing ...

24-Aug-19 - Zogenix Announces Acquisition of Modis Therapeutics, Inc.

“This transaction advances Zogenix's mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of ...

24-Aug-19 - Why Zogenix Stock Sank Today

Shares of Zogenix (NASDAQ: ZGNX) closed Monday about 8.5% lower, a decline precipitated by the biotech's announcement that it plans to ...

Zogenix Funding

DateAmountRoundLead InvestorsReference
2006-08-29$60.0MAClarus Ventures, Domain Associates LLCArticle
2006-09-28$60.0MUndisclosedClarus Ventures, Domain AssociatesArticle
2008-01-10$18.0MUndisclosedAbingworth Management LtdArticle
2008-07-29$18.0MUndisclosedOxford Finance Corporation, CIT Healthcare LLCArticle
2009-09-24$51.0MUndisclosedClarus Ventures, Domain AssociatesArticle
2009-12-08$35.0MUndisclosedChicago Growth Partners, Clarus VenturesArticle
2010-07-14$50.0MUndisclosedOxford Finance CorporationArticle
2011-09-19$69.0MUndisclosedArticle
2012-07-25$60.7MUndisclosedArticle
2013-11-05$60.0MUndisclosedStifelArticle
2013-11-14$64.4MUndisclosedArticle
2015-07-31$98.3MUndisclosedLeerink Partners LLCArticle
2017-10-04$288.9MUndisclosedLeerink Partners LLCArticle

Zogenix Executive Hires

DateNameTitleReference
2006-10-17J.D. HaldemanVP Commercial/Corp CommunicationsArticle
2007-06-08David NassifEVP/Chief Financial OfficerArticle
2008-04-18Cynthia RobinsonChief Development OfficerArticle
2010-03-02Ann D. RhoadsCFOArticle
2013-12-18Bradley S. GalerEVP/Chief Medical Officer.Article
2015-07-07Gail M. FarfelExecutive Vice President/Chief Development OfficerArticle
2017-01-09Michael SmithCFOArticle